Trending...
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- LAGOS PERSONALIZES ITS "SHOP PINK" INITIATIVE IN SUPPORT OF THE BREAST CANCER RESEARCH FOUNDATION®
- Inner Strength Education Welcomes New Instructors
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- In Celebration of National Careers in Construction Month, 84 Lumber is Looking for the Next Generation of Construction Professionals
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Sporttrade Announces Strategic Investor To Enhance Sports Betting Markets
- Pro Sound League: The Next Big Movement in Music Launching in 2025 – Join Us!
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Surge Institute Welcomes 2025 Philadelphia Cohort
- Bridge Cable Partners With Alarm.com To Expand Security Solutions
- Market Opportunities for a Startup Advisory Firm
- Sidow Sobrino's My Amir in the Running for GRAMMY® Nominations
- The Best Answer, Inc. Acquires Lluna, Inc., Expanding Its AI-Powered Culture Success Platform
- Reliance Aerotech Inc. Announces Appointment Of Ron Jordan To Chief Strategy Officer
- Stop Fighting, Start Living. Daryl Dittmer's New Book Offers Roadmap to Personal Power
- BTR: Understanding the Critical 2FA Vulnerability in QR Code Enrollment Processes Uncovered by Silent Sector – Lauro Chavez
- Mrs. T's Pierogies Celebrates National Pierogy Day on October 8 with Limited-Edition Merch That Will Keep You Warm and Cozy All Season Long
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Auto Depth Digital Wound Measurement Now Available on MolecuLightDX USA - English USA - Deutsch USA - Français
- Get in the Halloween Spirit at Rare Books LA Union Station
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- Grand opening of the ResC4EU platform to support companies withstanding supply chain disruptions
- Inner Strength Education Welcomes New Instructors
- LAGOS PERSONALIZES ITS "SHOP PINK" INITIATIVE IN SUPPORT OF THE BREAST CANCER RESEARCH FOUNDATION®
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- The Ultimate Guide to Buying Historic Luxury Homes in Winter Park, FL Now Available
- New Service Launched Unsecured Business Financing Based on Revenue—No Collateral Required
- And The Winner Is: Special Request Ft Rey T (AKA) Reynard Thomas